ASL di Salerno - PO Andrea tortora
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The research program at ASL di Salerno focuses on blood‑related cancers, notably Follicular Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, aiming to refine treatment intensity and improve patient outcomes.
- Optimizing chemotherapy cycles for high‑burden follicular lymphoma
- Evaluating novel combination regimens in relapsed/refractory CLL/SLL
- Assessing progression‑free survival benefits of tailored immunochemotherapy
These studies seek to determine whether reduced chemotherapy exposure can maintain effectiveness while lessening side effects, and to compare emerging drug combinations against established standards.
Neoplasms
In the neoplasm portfolio, the site investigates Acute Myeloid Leukemia with a focus on patients carrying the NPM1 mutation who cannot receive intensive chemotherapy, testing targeted agents alongside existing therapies.
- Assessing the impact of adding revumenib to azacitidine and venetoclax
- Exploring survival improvements for newly diagnosed NPM1‑mutated AML
- Providing less‑intensive treatment options for high‑risk patients
The goal is to enhance overall survival and remission rates by integrating precision‑medicine approaches into standard care pathways.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1BeOne Medicines AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ASL di Salerno - PO Andrea tortora
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Revumenib Combined with Azacitidine and Venetoclax in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML Patients Ineligible for Intensive Chemotherapy | Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | Phase III | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obinutuzumab | 2 | Unknown | 2021-12-01 | 2025-11-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.